top of page
Executive Spotlights

Biogen's $6.5B Acquisition of Reata: Powering Up Rare Disease Portfolio!

Cambridge, MA, July 28, 2023 (Reuters) -- Biogen (BIIB.O) has announced that it is acquiring Reata Pharmaceuticals (RETA.O), for almost $6.5 billion. This marks the first significant acquisition under the leadership of CEO Christopher Viehbacher, steering the drugmaker towards a path of growth.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page